<DOC>
	<DOCNO>NCT01491035</DOCNO>
	<brief_summary>The objective study evaluate pharmacokinetics vortioxetine metabolite connection multiple oral dose child adolescent patient DSM-IV-TR diagnosis Depressive Anxiety Disorder</brief_summary>
	<brief_title>Pharmacokinetics Tolerability Vortioxetine ( Lu AA21004 ) Child Adolescent Patients With Depressive Anxiety Disorder</brief_title>
	<detailed_description>The study conduct US Europe include paediatric patient diagnose depressive anxiety disorder two age population ; child age 7-11 year adolescents age 12-17 year . It open study allow pharmacokinetic ( PK ) sample patient four dose level test . Following low initial dos 2 6 day , patient treat daily assign dose level 14 day , expect patient may benefit treatment period . As treatment duration sufficient accord treatment guideline , judge indicated investigator , patient offer continue extension treatment six month allow possibility therapeutic satisfaction . Preferably , cohort dose follow order : AC1 , AC2 , CC1 , AC3 , CC2 , AC4 , CC3 , CC4 . An external data safety monitor board ( DSMB ) establish evaluate safety , tolerability preliminary PK data dose cohort ( ) prior dose subsequent cohort ( ) . The dose regimen may adjust base recommendation DSMB . Adolescents expose certain dose vortioxetine child receive dose .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients DSMIVTR diagnosis Depressive Anxiety Disorder . The patient parent ( ) /legal representative ( ) able comprehend satisfactorily comply protocol requirement . Treatment antidepressant therapy warrant , judge investigator . The patient pregnant breastfeeding . The patient present history Axis I ( DSMIVTR ) diagnosis Bipolar Disorder , Post Traumatic Stress Disorder ( PTSD ) , Autism , Pervasive Developmental Disorder ( PDD ) , Obsessive Compulsive Disorder ( OCD ) Schizophrenia Schizoaffective Disorder . The patient maintain stable dose methylphenidate amphetamine treatment attentiondeficit/hyperactivity disorder ( ADHD ) minimum 4 week prior study treatment . The patient know mental retardation , clinical evidence know social school history indicative mental retardation . The patient significant risk commit suicide base history ( example previous suicide attempt ) accord investigator 's experience , base active suicidal ideation , intent plan , item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) . The subject concurrent illness may affect particular target absorption , distribution , elimination investigational medicinal product ( IMP ) . The patient meet DSMIVTR criterion psychoactive substance alcohol use disorder . Other inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>